The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Key considerations when preparing patients with ALL for CAR T-cell therapy
José María Ribera
Anita Rijneveld
Andrea Biondi
André BaruchelKey considerations when preparing patients with ALL for CAR T-cell therapy
During the ALL Hub Steering Committee meeting, André Baruchel chaired a discussion on “What are the key considerations when preparing patients with ALL for CAR T-cell therapy ?”, featuring Andrea Biondi, Anita Rijneveld, and José María Ribera.
The discussion topics included:
-
Key considerations when selecting patients: stable disease, degree of antigen expression, burden of bone marrow disease, and number of circulating tumor blasts
-
Bridging therapy and lymphodepletion considerations
-
The impact of prior exposure to blinatumomab and inotuzumab on CAR T-cell outcomes
-
Indications for the use of tisagenlecleucel in pediatric ALL
-
Indications for the use of brexucabtagene autoleucel in adult ALL
Key considerations when preparing patients with ALL for CAR T-cell therapy